DHE in the pharmacotherapy of migraine: Potential for a larger role

Joel R. Saper, Stephen Silberstein, David William Dodick, Alan Rapoport

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Despite a large array of currently marketed, frequently effective drugs for the acute treatment of migraine headache, comprising various classes and formulations, predictably reliable treatment for most headache types is often lacking. Dihydroergotamine mesylate (DHE) is a comparatively safe and effective therapy for migraine headache that could potentially be used for a broader range of headache types than occurs at present. The features of DHE supporting this assertion include (1) effectiveness in terminating severe, long-lasting headaches, (2) rapid onset of action, (3) very low rates of headache recurrence, (4) minimal risk of medication-overuse headache, and (5) in the nasal spray formulation, suitability for outpatients (especially patients who are very nauseated or vomiting, potentially obviating the need for an office or hospital visit for acute care). Conditions or circumstances for which there are data supporting the expanded use of DHE include menstrual migraine, migraine with central sensitization and cutaneous allodynia, medication-overuse headache, migraine recurrence, and status migrainosus. The introduction of the intranasal formulation of DHE provides both pharmacologic and patient-convenience advantages for use in migraine therapy. This article reviews the rationale for the use of DHE in these common, often difficult-to-treat migraine forms.

Original languageEnglish (US)
JournalHeadache
Volume46
Issue numberSUPPL. 4
DOIs
StatePublished - Nov 2006

Fingerprint

Dihydroergotamine
Migraine Disorders
Drug Therapy
Secondary Headache Disorders
Headache
Central Nervous System Sensitization
Nasal Sprays
Recurrence
Hyperalgesia
Therapeutics
Vomiting
Outpatients
Skin

Keywords

  • Central sensitization
  • Cutaneous allodynia
  • Dihydroergotamine mesylate
  • Headache prevalence
  • Intranasal spray
  • Medication overuse headache
  • Menstrual migraine
  • Migraine
  • Migraine therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

DHE in the pharmacotherapy of migraine : Potential for a larger role. / Saper, Joel R.; Silberstein, Stephen; Dodick, David William; Rapoport, Alan.

In: Headache, Vol. 46, No. SUPPL. 4, 11.2006.

Research output: Contribution to journalArticle

Saper, Joel R. ; Silberstein, Stephen ; Dodick, David William ; Rapoport, Alan. / DHE in the pharmacotherapy of migraine : Potential for a larger role. In: Headache. 2006 ; Vol. 46, No. SUPPL. 4.
@article{4f96de3101314056aae4265023003825,
title = "DHE in the pharmacotherapy of migraine: Potential for a larger role",
abstract = "Despite a large array of currently marketed, frequently effective drugs for the acute treatment of migraine headache, comprising various classes and formulations, predictably reliable treatment for most headache types is often lacking. Dihydroergotamine mesylate (DHE) is a comparatively safe and effective therapy for migraine headache that could potentially be used for a broader range of headache types than occurs at present. The features of DHE supporting this assertion include (1) effectiveness in terminating severe, long-lasting headaches, (2) rapid onset of action, (3) very low rates of headache recurrence, (4) minimal risk of medication-overuse headache, and (5) in the nasal spray formulation, suitability for outpatients (especially patients who are very nauseated or vomiting, potentially obviating the need for an office or hospital visit for acute care). Conditions or circumstances for which there are data supporting the expanded use of DHE include menstrual migraine, migraine with central sensitization and cutaneous allodynia, medication-overuse headache, migraine recurrence, and status migrainosus. The introduction of the intranasal formulation of DHE provides both pharmacologic and patient-convenience advantages for use in migraine therapy. This article reviews the rationale for the use of DHE in these common, often difficult-to-treat migraine forms.",
keywords = "Central sensitization, Cutaneous allodynia, Dihydroergotamine mesylate, Headache prevalence, Intranasal spray, Medication overuse headache, Menstrual migraine, Migraine, Migraine therapy",
author = "Saper, {Joel R.} and Stephen Silberstein and Dodick, {David William} and Alan Rapoport",
year = "2006",
month = "11",
doi = "10.1111/j.1526-4610.2006.00605.x",
language = "English (US)",
volume = "46",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "SUPPL. 4",

}

TY - JOUR

T1 - DHE in the pharmacotherapy of migraine

T2 - Potential for a larger role

AU - Saper, Joel R.

AU - Silberstein, Stephen

AU - Dodick, David William

AU - Rapoport, Alan

PY - 2006/11

Y1 - 2006/11

N2 - Despite a large array of currently marketed, frequently effective drugs for the acute treatment of migraine headache, comprising various classes and formulations, predictably reliable treatment for most headache types is often lacking. Dihydroergotamine mesylate (DHE) is a comparatively safe and effective therapy for migraine headache that could potentially be used for a broader range of headache types than occurs at present. The features of DHE supporting this assertion include (1) effectiveness in terminating severe, long-lasting headaches, (2) rapid onset of action, (3) very low rates of headache recurrence, (4) minimal risk of medication-overuse headache, and (5) in the nasal spray formulation, suitability for outpatients (especially patients who are very nauseated or vomiting, potentially obviating the need for an office or hospital visit for acute care). Conditions or circumstances for which there are data supporting the expanded use of DHE include menstrual migraine, migraine with central sensitization and cutaneous allodynia, medication-overuse headache, migraine recurrence, and status migrainosus. The introduction of the intranasal formulation of DHE provides both pharmacologic and patient-convenience advantages for use in migraine therapy. This article reviews the rationale for the use of DHE in these common, often difficult-to-treat migraine forms.

AB - Despite a large array of currently marketed, frequently effective drugs for the acute treatment of migraine headache, comprising various classes and formulations, predictably reliable treatment for most headache types is often lacking. Dihydroergotamine mesylate (DHE) is a comparatively safe and effective therapy for migraine headache that could potentially be used for a broader range of headache types than occurs at present. The features of DHE supporting this assertion include (1) effectiveness in terminating severe, long-lasting headaches, (2) rapid onset of action, (3) very low rates of headache recurrence, (4) minimal risk of medication-overuse headache, and (5) in the nasal spray formulation, suitability for outpatients (especially patients who are very nauseated or vomiting, potentially obviating the need for an office or hospital visit for acute care). Conditions or circumstances for which there are data supporting the expanded use of DHE include menstrual migraine, migraine with central sensitization and cutaneous allodynia, medication-overuse headache, migraine recurrence, and status migrainosus. The introduction of the intranasal formulation of DHE provides both pharmacologic and patient-convenience advantages for use in migraine therapy. This article reviews the rationale for the use of DHE in these common, often difficult-to-treat migraine forms.

KW - Central sensitization

KW - Cutaneous allodynia

KW - Dihydroergotamine mesylate

KW - Headache prevalence

KW - Intranasal spray

KW - Medication overuse headache

KW - Menstrual migraine

KW - Migraine

KW - Migraine therapy

UR - http://www.scopus.com/inward/record.url?scp=33750432455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750432455&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4610.2006.00605.x

DO - 10.1111/j.1526-4610.2006.00605.x

M3 - Article

C2 - 17078853

AN - SCOPUS:33750432455

VL - 46

JO - Headache

JF - Headache

SN - 0017-8748

IS - SUPPL. 4

ER -